Clinical application of OCTA in patients with central serous chorioretinopathy treat wit f 577-nm yellow subthreshold micropulse laser

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049476

Enrollment

Unknown

Registered

2021-08-02

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central serous chorioretinopathy

Interventions

Experimental group:micropulse laser

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old; 2. Visual symptoms <= 3 months; 3. The first illness.

Exclusion criteria

Exclusion criteria: 1. Chronic CSC (duration > 3 months) or recurrent chronic CSC; 2. Macular diseases, such as polypoid choroidal vasculopathy and age-related macular degeneration; 3. Eyes with a history of laser photocoagulation (LP) treatment, photodynamic therapy (PDT) or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection; 4. Pregnancy, history of steroid use and systemic diseases such as endogenous hypercortisolism and diabetes.

Design outcomes

Primary

Measure	Time frame
best corrected visual acuity;foveal thickness;	—

Countries

China

Contacts

Public ContactQin bing

Suqian First Pepple’s Hospital

qinbing80821@sina.com+86 18012186620

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026